1. The Plasma Level of Interleukin-1β Can Be a Biomarker of Angiopathy in Systemic Chronic Active Epstein–Barr Virus Infection.
- Author
-
Ohashi, Ayaka, Uemura, Yu, Yoshimori, Mayumi, Wada, Naomi, Imadome, Ken-Ichi, Yudo, Kazuo, Koyama, Takatoshi, Shimizu, Norio, Nishio, Miwako, and Arai, Ayako
- Subjects
EPSTEIN-Barr virus diseases ,VASCULAR endothelial cells ,BIOMARKERS ,MONONUCLEOSIS ,T cells - Abstract
Systemic chronic active Epstein–Barr virus infection (sCAEBV) is an EBV-positive T- or NK-cell neoplasm revealing persistent systemic inflammation. Twenty-five percent of sCAEBV patients accompany angiopathy. It is crucial to clarify the mechanisms of angiopathy development in sCAEBV because angiopathy is one of the main causes of death. Interleukin-1β (IL-1β) is reported to be involved in angiopathy onset. We investigated if IL-1β plays a role as the inducer of angiopathy of sCAEBV. We detected elevated IL-1β levels in four out of 17 sCAEBV patient's plasma. Interestingly, three out of the four had clinically associated angiopathy. None of the other patients with undetectable level of IL-1β had angiopathy. In all patients with high plasma levels of IL-1β and vascular lesions, EBV-infected cells were CD4-positive T cells. In one patient with high plasma IL-1β, the level of IL-1β mRNA of the monocytes was 17.2 times higher than the level of the same patient's EBV-infected cells in peripheral blood. In Ea.hy926 cells, which are the models of vascular endothelial cells, IL-1β inhibited the proliferation and induced the surface coagulation activity. IL-1β is a potent biomarker and a potent therapeutic target to treat sCAEBV accompanying angiopathy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF